{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:11:05Z","timestamp":1789161065841,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013003","name":"Universit\u00e0 degli Studi di Cagliari","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>It is well known that interferon-\u03b1 (IFN-\u03b1), used for long time as the main therapy for HCV-related disease, induces thyroid alterations, but the impact of the new direct-acting antivirals (DAAs) on thyroid is not established. Aim of this prospective study was to evaluate if DAAs therapy may induce thyroid alterations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 113 HCV patients, subdivided at the time of the enrollment in na\u00efve group (<jats:italic>n<\/jats:italic>\u2009=\u200964) and in IFN-\u03b1 group (<jats:italic>n<\/jats:italic>\u2009=\u200949) previously treated with pegylated interferon-\u03b1 and ribavirin, were evaluated for thyroid function and autoimmunity before and after 20\u201332\u00a0weeks of DAAs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Before starting DAAs, a total of 8\/113 (7.1%) patients showed Hashimoto's thyroiditis (HT) all belonging to IFN-\u03b1 group (8\/49, 16.3%), while no HT cases were found in the na\u00efve group. Overall, 7\/113 (6.2%) patients were hypothyroid: 3\/64 (4.7%) belonging to na\u00efve group and 4\/49 (8.2%) to IFN-\u03b1 group. Furthermore, a total of 8\/113 patients (7.1%) showed subclinical hyperthyroidism: 2\/64 (3.1%) were from na\u00efve group and 6\/49 (12.2%) from IFN-\u03b1 group. Interestingly, after DAAs therapy, no new cases of HT, hypothyroidism and hyperthyroidism was found in all series, while 6\/11 (54.5%) patients with non-autoimmune subclinical thyroid dysfunction became euthyroid. Finally, the only association between viral genotypes and thyroid alterations was genotype 1 and hypothyroidism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study supports evidence that DAAs have a limited or missing influence on thyroid in patients with HCV-related diseases. Moreover, it provides preliminary evidence that subclinical non-autoimmune thyroid dysfunction may improve after HCV infection resolution obtained by DAAs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-01909-0","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T09:04:12Z","timestamp":1662023052000},"page":"359-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity"],"prefix":"10.1007","volume":"46","author":[{"given":"R.","family":"Rodia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. E.","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Balestrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Onali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Perra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Littera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Velluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9924-5192","authenticated-orcid":false,"given":"F.","family":"Boi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"1909_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.15403\/jgld.2014.1121.252.chc","volume":"25","author":"Y Shen","year":"2016","unstructured":"Shen Y, Wang XL, Xie JP, Shao JG, Lu YH, Zhang S, Qin G (2016) Thyroid disturbance in patients with chronic hepatitis c infection: a systematic review and meta-analysis. J Gastrointestin Liver Dis 25:227\u2013234. https:\/\/doi.org\/10.15403\/jgld.2014.1121.252.chc","journal-title":"J Gastrointestin Liver Dis"},{"issue":"7","key":"1909_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/JHC.S221187","volume":"15","author":"S Dash","year":"2020","unstructured":"Dash S, Aydin Y, Widmer KE, Nayak L (2020) Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment. J Hepatocell Carcinoma 15(7):45\u201376. https:\/\/doi.org\/10.2147\/JHC.S221187","journal-title":"J Hepatocell Carcinoma"},{"key":"1909_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3904\/kjim.2015.30.6.792","volume":"30","author":"Y Hwang","year":"2015","unstructured":"Hwang Y, Kim W, Kwon SY, Yu HM, Kim JH, Choe WH (2015) Incidence of and risk factors for thyroid dysfunction during peginterferon \u03b1 and ribavirin treatment in patients with chronic hepatitis C. Korean J Intern Med 30:792\u2013800. https:\/\/doi.org\/10.3904\/kjim.2015.30.6.792","journal-title":"Korean J Intern Med"},{"key":"1909_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF03346699","volume":"34","author":"F Menconi","year":"2011","unstructured":"Menconi F, Hasham A, Tomer Y (2011) Environmental triggers of thyroiditis: hepatitis C and interferon-\u03b1. J Endocrinol Invest 34:78\u201384. https:\/\/doi.org\/10.1007\/BF03346699","journal-title":"J Endocrinol Invest"},{"key":"1909_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1210\/jcem.80.3.7883851","volume":"80","author":"A Imagawa","year":"1995","unstructured":"Imagawa A, Itoh N, Hanafusa T, Oda Y, Waguri M, Miyagawa J, Kono N, Kuwajima M, Matsuzawa Y (1995) Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 80:922\u2013926. https:\/\/doi.org\/10.1210\/jcem.80.3.7883851","journal-title":"J Clin Endocrinol Metab"},{"key":"1909_CR6","first-page":"399","volume":"89","author":"U Watanabe","year":"1994","unstructured":"Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N (1994) The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 89:399\u2013403","journal-title":"Am J Gastroenterol"},{"key":"1909_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1046\/j.1365-2265.1996.751768.x","volume":"44","author":"M Marazuela","year":"1996","unstructured":"Marazuela M, Garc\u00eda-Buey L, Gonz\u00e1lez-Fern\u00e1ndez B, Garc\u00eda-Monz\u00f3n C, Arranz A, Borque MJ, Moreno-Otero R (1996) Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 44:635\u2013642. https:\/\/doi.org\/10.1046\/j.1365-2265.1996.751768.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1909_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1089\/thy.2012.0565","volume":"23","author":"JS Mammen","year":"2013","unstructured":"Mammen JS, Ghazarian SR, Rosen A, Ladenson PW (2013) Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C. Thyroid 23:1151\u20131158. https:\/\/doi.org\/10.1089\/thy.2012.0565","journal-title":"Thyroid"},{"key":"1909_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1365-2265.1993.tb02423.x","volume":"39","author":"E Baudin","year":"1993","unstructured":"Baudin E, Marcellin P, Pouteau M, Colas-Linhart N, Le Floch JP, Lemmonier C, Benhamou JP, Bok B (1993) Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf) 39:657\u2013661. https:\/\/doi.org\/10.1111\/j.1365-2265.1993.tb02423.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1909_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.beem.2009.07.004","volume":"23","author":"Y Tomer","year":"2009","unstructured":"Tomer Y, Menconi F (2009) Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 23:703\u2013712. https:\/\/doi.org\/10.1016\/j.beem.2009.07.004","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"373","key":"1909_CR11","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"31","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S, ASTRAL-1 Investigators (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 31(373):2599\u20132607. https:\/\/doi.org\/10.1056\/NEJMoa1512610","journal-title":"N Engl J Med"},{"issue":"373","key":"1909_CR12","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"31","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, Br\u00e4u N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourli\u00e8re M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M, ASTRAL-2 Investigators; ASTRAL-3 Investigators (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 31(373):2608\u20132617. https:\/\/doi.org\/10.1056\/NEJMoa1512612","journal-title":"N Engl J Med"},{"key":"1909_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","volume":"151","author":"E Gane","year":"2016","unstructured":"Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ (2016) High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology 151:651-659.e1. https:\/\/doi.org\/10.1053\/j.gastro.2016.07.020","journal-title":"Gastroenterology"},{"issue":"378","key":"1909_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"25","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourli\u00e8re M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ (2018) Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 25(378):354\u2013369. https:\/\/doi.org\/10.1056\/NEJMoa1702417","journal-title":"N Engl J Med"},{"key":"1909_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ (2017) Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis. J Hepatol 67:263\u2013271. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.039","journal-title":"J Hepatol"},{"key":"1909_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"M Puoti","year":"2018","unstructured":"Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS, Marinho R, Dufour JF, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Zhang Z, Lovell S, Pilot-Matias T, Mensa FJ (2018) High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis. J Hepatol 69:293\u2013300. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.007","journal-title":"J Hepatol"},{"key":"1909_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14656566.2018.1444030","volume":"19","author":"AF Carrion","year":"2018","unstructured":"Carrion AF, Martin P (2018) Glecaprevir + pibrentasvir for treatment of hepatitis C. Expert Opin Pharmacother 19:413\u2013419. https:\/\/doi.org\/10.1080\/14656566.2018.1444030","journal-title":"Expert Opin Pharmacother"},{"key":"1909_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/jcu.20008","volume":"32","author":"M Loy","year":"2004","unstructured":"Loy M, Cianchetti ME, Cardia F, Melis A, Boi F, Mariotti S (2004) Correlation of computerized gray-scale sonographic findings with thyroid function and thyroid autoimmune activity in patients with Hashimoto\u2019s thyroiditis. J Clin Ultrasound 32:136\u2013140. https:\/\/doi.org\/10.1002\/jcu.20008","journal-title":"J Clin Ultrasound"},{"key":"1909_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/thy.2000.10.251","volume":"10","author":"OM Pedersen","year":"2000","unstructured":"Pedersen OM, Aardal NP, Larssen TB, Varhaug JE, Myking O, Vik-Mo H (2000) The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid 10:251\u2013259. https:\/\/doi.org\/10.1089\/thy.2000.10.251","journal-title":"Thyroid"},{"key":"1909_CR20","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1089\/thy.2007.0014","volume":"17","author":"Y Ito","year":"2007","unstructured":"Ito Y, Amino N, Yokozawa T, Ota H, Ohshita M, Murata N, Morita S, Kobayashi K, Miyauchi A (2007) Ultrasonographic evaluation of thyroid nodules in 900 patients: comparison among ultrasonographic, cytological, and histological findings. Thyroid 17:1269\u20131276. https:\/\/doi.org\/10.1089\/thy.2007.0014","journal-title":"Thyroid"},{"key":"1909_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40618-017-0757-0","volume":"41","author":"F Boi","year":"2018","unstructured":"Boi F, Pani F, Cal\u00f2 PG, Lai ML, Mariotti S (2018) High prevalence of papillary thyroid carcinoma in nodular Hashimoto\u2019s thyroiditis at the first diagnosis and during the follow-up. J Endocrinol Invest 41:395\u2013402. https:\/\/doi.org\/10.1007\/s40618-017-0757-0","journal-title":"J Endocrinol Invest"},{"issue":"263","key":"1909_CR22","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jama.1990.03440110095035","volume":"16","author":"MI Surks","year":"1990","unstructured":"Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH (1990) American thyroid association guidelines for use of laboratory tests in thyroid disorders. JAMA 16(263):1529\u20131532","journal-title":"JAMA"},{"issue":"291","key":"1909_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.291.2.228","volume":"14","author":"MI Surks","year":"2004","unstructured":"Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 14(291):228\u2013238. https:\/\/doi.org\/10.1001\/jama.291.2.228","journal-title":"JAMA"},{"key":"1909_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1210\/jc.2013-2409","volume":"99","author":"A GarmendiaMadariaga","year":"2014","unstructured":"GarmendiaMadariaga A, Santos Palacios S, Guill\u00e9n-Grima F, Galofr\u00e9 JC (2014) The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 99:923\u2013931. https:\/\/doi.org\/10.1210\/jc.2013-2409","journal-title":"J Clin Endocrinol Metab"},{"key":"1909_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12020-012-9703-2","volume":"42","author":"DS McLeod","year":"2012","unstructured":"McLeod DS, Cooper DS (2012) The incidence and prevalence of thyroid autoimmunity. Endocrine 42:252\u2013265. https:\/\/doi.org\/10.1007\/s12020-012-9703-2","journal-title":"Endocrine"},{"issue":"1","key":"1909_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1530\/EJE-14-0182","volume":"171","author":"AP Delitala","year":"2014","unstructured":"Delitala AP, Pilia MG, Ferreli L, Loi F, Curreli N, Balaci L, Schlessinger D, Cucca F (2014) Prevalence of unknown thyroid disorders in a Sardinian cohort. Eur J Endocrinol 171(1):143\u2013149. https:\/\/doi.org\/10.1530\/EJE-14-0182","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1909_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/BF03343626","volume":"22","author":"A Loviselli","year":"1999","unstructured":"Loviselli A, Oppo A, Velluzzi F, Atzeni F, Mastinu GL, Farci P, Orgiana G, Balestrieri A, Cocco PL, Mariotti S (1999) Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in north-western Sardinia. J Endocrinol Invest 22(9):660\u2013665. https:\/\/doi.org\/10.1007\/BF03343626","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1909_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40345-017-0114-4","volume":"6","author":"A Bocchetta","year":"2018","unstructured":"Bocchetta A, Ambrosiani L, Baggiani G, Pisanu C, Chillotti C, Ardau R, Velluzzi F, Piras D, Loviselli A, Pani A (2018) Circulating antithyroid antibodies contribute to the decrease of glomerular filtration rate in lithium-treated patients: a longitudinal study. Int J Bipolar Disord 6(1):3. https:\/\/doi.org\/10.1186\/s40345-017-0114-4","journal-title":"Int J Bipolar Disord"},{"key":"1909_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/jmv.25319","volume":"91","author":"B Wahid","year":"2019","unstructured":"Wahid B, Waqar M, Rasool N, Wasim M, Khalid I, Idrees M (2019) Prevalence of thyroid stimulating hormone dysfunction among sofosbuvir-treated HCV-infected patients: a real-world clinical experience. J Med Virol 91:514\u2013517. https:\/\/doi.org\/10.1002\/jmv.25319","journal-title":"J Med Virol"},{"key":"1909_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25931","author":"B Wahid","year":"2020","unstructured":"Wahid B, Shami K, Joiya SA, \u00d6zuyar SEG, Idrees M (2020) Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin). J Med Virol. https:\/\/doi.org\/10.1002\/jmv.25931","journal-title":"J Med Virol"},{"key":"1909_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12072-018-9845-2","volume":"12","author":"R Eletreby","year":"2018","unstructured":"Eletreby R, Said M, Abdellatif Z, Saad Y, ElSerafy M, Dabes H, ElSaeed K, El-Shazly Y, Doss W (2018) High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy. Hepatol Int 12:143\u2013148. https:\/\/doi.org\/10.1007\/s12072-018-9845-2","journal-title":"Hepatol Int"},{"issue":"105","key":"1909_CR32","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1210\/clinem\/dgz241","volume":"1","author":"SS Hammerstad","year":"2020","unstructured":"Hammerstad SS, Blackard JT, Lombardi A, Owen RP, Concepcion E, Yi Z, Zhang W, Tomer Y (2020) Hepatitis C virus Infection of human thyrocytes: metabolic, hormonal, and immunological implications. J Clin Endocrinol Metab 1(105):1157\u20131168. https:\/\/doi.org\/10.1210\/clinem\/dgz241","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01909-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01909-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01909-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:19:57Z","timestamp":1674260397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01909-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["1909"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01909-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University of Cagliari approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}